Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vivimed Labs Ltd To acquire Finoso Pharma Private Limited-Business Standard


Thursday, 14 Feb 2013 03:14am EST 

Business Standard reported that Vivimed Labs Ltd has proposed to acquire city-based Finoso Pharma Private Limited, a pharmaceutical development services company focused on formulations product development efforts for multiple markets and develops globally accepted dossiers. The proposed acquisition will be done for a total consideration of INR15 crore (INR150 million) comprising cash, stock and deferred payment, and will be debt free, according to a company press release. After acquisition, Finoso will become Vivimed’s research and development (R&D) unit to support innovators, generics and licensing efforts. 

Company Quote

309.05
-0.55 -0.18%
21 Aug 2014